Investment opportunity in health-care space unveiled
Fund manager Manulife Asset Management Trust Corp. (MAMTC) has unveiled a new investment fund that allows investors to buy into the global health-care space and ride on breakthrough medical advances.
Manulife Global Healthcare Equity Feeder Fund is an equity feeder unit investment trust fund (UITF) that investors with aggressive risk appetite may access for as low as P5,000 or $100.
“The global health-care industry presents potentially profitable long-term investment opportunities in advancements focused on disease prevention, as in the case of the COVID-19 vaccine, as well as developments in central nervous system disorders, obesity or metabolic syndrome, and other rare cases. Around the world, we see increases in health-related expenditures, particularly in countries with aging populations,” MAMTC president and chief executive officer Aira Gaspar said in a statement.
“The fund will enable investors to take advantage of the health-care sector’s exciting growth potential at a time when its value to economies and societies has become more important,” she added.
This UITF’s target fund, Manulife Global Fund-Healthcare Fund, seeks innovative companies that have achieved groundbreaking progress in understanding previously untreatable or undertreated conditions. The target fund also seeks underappreciated market opportunities related to medical breakthroughs and companies that are well-positioned to bend the health-care cost curve via products, services or technologies.
Amid aging population and rising health-care costs in many parts of the globe, the fund aims to invest in companies that are well-positioned to benefit from the growing demand for health care and those that are capable of serving unmet medical needs.
Article continues after this advertisementThe minimum holding period is 30 days, with an early redemption charge of 1 percent. Trust fee is 1.75 percent a year.
MAMTC was recognized as one of the Philippines’ top investment houses by The Asset Benchmark Research Review 2020. —DORIS DUMLAO-ABADILLA INQ
